[ORGANIZATION]
GLP‑1 agonist class
Featured in 1 tracked story · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
112 clusters · 548 sources · last updated
Latest: Novo Nordisk faces intense competition in obesity drug market
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,